NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PHOTOFRIN (porfimer sodium) by Pinnacle Spine is 12. First approved in 1995.
Drug data last refreshed 20m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTOFRIN (porfimer sodium) is a photosensitizing agent used in photodynamic therapy (PDT), a two-stage cancer treatment combining intravenous drug administration with 630 nm laser light activation. The drug generates singlet oxygen and free radicals that cause tumor cell death through both direct cytotoxic effects and vascular occlusion. It is selective for tumor tissue due to preferential retention and light delivery targeting.
LOE Approaching
Product approaching loss of exclusivity with limited market presence (0 linked jobs), signaling a small, stable team with declining commercial momentum.
Mechanism of Action
12.1 Mechanism of Action The cytotoxic and antitumor actions of PHOTOFRIN are light and oxygen dependent. Photodynamic therapy (PDT) with PHOTOFRIN is a two-stage process. The first stage is the intravenous administration of PHOTOFRIN. Clearance from a variety of tissues occurs over 40-72 hours,…
Worked on PHOTOFRIN at Pinnacle Spine? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.